CVRX
Company Description
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 56.65M | 51.29M | 39.30M | 22.47M | 13.04M | 6.05M | 6.26M |
| Net Income | (53.31M) | (59.97M) | (41.20M) | (41.43M) | (43.08M) | (14.11M) | (14.63M) |
| EPS | -2.04 | -2.65 | -1.99 | -2.02 | -2.11 | -0.73 | -0.76 |
| Free Cash Flow | (40.75M) | (40.51M) | (39.61M) | (43.36M) | (28.91M) | (16.41M) | (12.89M) |
| FCF / Share | -1.56 | -1.79 | -1.91 | -2.11 | -1.40 | -42.39 | -26.71 |
| Operating CF | (40.17M) | (39.14M) | (39.02M) | (42.68M) | (27.73M) | (16.10M) | (12.79M) |
| Total Assets | 104.79M | 133.41M | 115.23M | 124.94M | 152.55M | 64.78M | 29.11M |
| Total Debt | 50.79M | 50.43M | 30.61M | 7.09M | 0 | 19.28M | 18.99M |
| Cash & Equiv | 75.71M | 105.93M | 90.57M | 106.19M | 142.07M | 59.11M | 25.74M |
| Book Value | 39.32M | 71.06M | 75.95M | 109.18M | 145.96M | (293.24M) | (279.04M) |
| Return on Equity | -1.36 | -0.84 | -0.54 | -0.38 | -0.30 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.77M | 16.02M | 14.69M | 13.59M | 12.35M | 15.34M | 13.37M | 11.81M | 10.77M | 11.30M | 10.51M | 9.50M |
| Net Income | (13.12M) | (11.93M) | (12.87M) | (14.74M) | (13.77M) | (10.65M) | (13.10M) | (14.03M) | (22.19M) | (9.16M) | (9.01M) | (11.65M) |
| EPS | -0.50 | -0.46 | -0.49 | -0.57 | -0.53 | -0.43 | -0.57 | -0.65 | -1.04 | -0.44 | -0.43 | -0.56 |
| Free Cash Flow | (12.29M) | (9.83M) | (10.00M) | (8.04M) | (12.88M) | (8.06M) | (10.45M) | (10.19M) | (11.81M) | (8.01M) | (8.16M) | (12.95M) |
| FCF / Share | -0.47 | -0.37 | -0.38 | -0.31 | -0.50 | -0.36 | -0.46 | -0.47 | -0.56 | -0.39 | -0.39 | -0.63 |
| Operating CF | (12.16M) | (9.76M) | (9.71M) | (7.94M) | (12.77M) | (8.01M) | (10.41M) | (9.83M) | (10.90M) | (7.84M) | (8.12M) | (12.81M) |
| Total Assets | 99.73M | 104.79M | 111.33M | 119.56M | 129.59M | 133.41M | 127.67M | 95.98M | 106.17M | 115.23M | 106.40M | 114.97M |
| Total Debt | 59.40M | 50.79M | 50.52M | 50.54M | 50.42M | 50.43M | 50.44M | 30.59M | 30.60M | 30.61M | 15.38M | 15.38M |
| Cash & Equiv | 72.30M | 75.71M | 85.12M | 95.03M | 102.67M | 105.93M | 100.16M | 70.40M | 80.11M | 90.57M | 82.99M | 90.81M |
| Book Value | 29.11M | 39.32M | 48.05M | 57.93M | 69.36M | 71.06M | 65.18M | 55.25M | 66.26M | 75.95M | 82.83M | 89.96M |
| Return on Equity | -0.45 | -0.30 | -0.27 | -0.25 | -0.20 | -0.15 | -0.20 | -0.25 | -0.33 | -0.12 | -0.11 | -0.13 |
